Sign in to view content

Effect of Fluocinolone Acetonide 0.2µg/day (ILUVIEN®) Implant on the Decision to Drive in Patients With Differential Control of DME

Seenu M. Hariprasad, MD

Video
Published 2018

Related

Dual Targeting VEGF/Ang3 Surrobody in an Experimental Model of Neovascularization
Jeffrey L. Olson, MD
Annual Meeting Talks
2019
Progression of diabetic retinopathy in patients treated with 0.2 μg/day
Raymond Iezzi, MD, MS
Updates from the Field
2017
A Novel Biocompatible Film to Promote Retinals Breaks Repair and Macular Hole Closure
Stanislao Rizzo, MD
Annual Meeting Talks
2018

Category: Diabetic Retinopathy

See more